Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
6 participants
INTERVENTIONAL
2008-04-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer
NCT01426620
Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
NCT03628144
Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
NCT00619021
Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC
NCT00378404
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
NCT00621049
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Recent studies in animals have shown that berries, given as a dietary supplement, are highly effective against certain types of cancers. In a study involving mice with lung tumors, mice that had consumed a mixture of berries developed fewer tumors and had less tumor growth than mice that did not consume berries.
The berries used in this study will consist of blueberries, black raspberries, or a mixture of both.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
berry powder
All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.
The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.
All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* adult men, adult women with no child bearing potential (hysterectomy, tubal ligation, post-menopausal women)
Exclusion Criteria
* women who are pregnant, or planning for pregnancy
* history of lung transplant
* prison inmate
* inability to take oral medication or food
* known or suspected allergy to berries or berry products
* HIV patients
* women who are on hormone replacement therapy
* women who are pregnant, or planning for pregnancy
* history of lung transplant
* prison inmate
* inability to take oral medication or food
* known or suspected allergy to berries or berry products
* HIV patients
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
James Graham Brown Cancer Center
OTHER
University of Louisville
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ramesh Gupta
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ramesh Gupta, PhD
Role: PRINCIPAL_INVESTIGATOR
James Graham Brown Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
James Graham Brown Cancer Center
Louisville, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCC-LUN-07-002
Identifier Type: OTHER
Identifier Source: secondary_id
08.0040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.